Pleomorphic phenotypes of gastrointestinal stromal tumors at metastatic sites with or without imatinib treatment

Cancer Science

Volumn 101, Issue 5, 2010, Pages 1270-1278

  Sakamoto, Kazuha ^a   Sakurai, Shinji ^a   Kanda, Tatsuo ^b   Sakuma, Yuji ^c   Hishima, Tsunekazu ^d   Hironaka, Mitsugu ^e   Bamba, Takeo ^b   Keira, Yoshiko ^f   Takano, Yasuo ^g   Niki, Toshiro ^e   Hasegawa, Tadashi ^f   Hirota, Seiichi ^h  

^a GUNMA UNIVERSITY   (Japan)

^b NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^c KANAGAWA CANCER CENTER   (Japan)

^d TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^e JICHI MEDICAL UNIVERSITY   (Japan)

^f SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g UNIVERSITY OF TOYAMA   (Japan)

^h HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CISPLATIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMATINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN TYROSINE KINASE; SCATTER FACTOR RECEPTOR; STEM CELL FACTOR;

ADULT; AGED; ANTICOAGULANT THERAPY; ANTIGEN EXPRESSION; ARTICLE; ARTIFICIAL EMBOLISM; AUTOPSY; CANCER MORTALITY; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; EXON; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SURGERY; GASTROINTESTINAL TUMOR; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTHERMIA; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; MISSENSE MUTATION; MORPHOMETRICS; PHENOTYPE; PLEOMORPHIC ADENOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; ANTIGENS, CD34; ANTINEOPLASTIC AGENTS; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA;

EID: 77953192864     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01510.x     Document Type: Article

References (31)

1. Miettinen M, Lasota J. Gastrointestinal stromal tumors-definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001, 438:1-12.
2. Fletcher CD, Berman JJ, Corless C. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002, 33:459-65.
3. Hirota S, Isozaki K, Moriyama Y. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998, 279:577-80.
4. Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, Miettinen M. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol 1998, 11:728-34.
5. Rubin BP, Singer S, Tsao C. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001, 61:8118-21.
6. Lux ML, Rubin BP, Biase TL. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol 2000, 156:791-5.
7. Heinrich MC, Corless CL, Duensing A. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003, 299:708-10.
8. Lasota J, Miettinen M. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology 2008, 53:245-66.
9. Dematri GD, von Mehren M, Blanke CD. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002, 347:472-80.
10. Verweij J, Casali PG, Zalcberg J. Progression-free survival in gastrointestinal stromal tumors with high-dose imatinib: randomised trial. Lancet 2004, 364:1127-34.
11. Debiec-Rychter M, Cools J, Dumez H. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology 2005, 128:270-9.
12. Heinrich MC, Corless CL, Blanke CD. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 2006, 24:4764-74.
13. Cassier PA, Dufresne A, Arifi S. Novel approaches to gastrointestinal stromal tumors resistant to imatinib and sunitinib. Curr Gastroenterol Rep 2008, 10:555-61.
14. Heinrich MC, Maki RG, Corless CL. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. Clin Oncol 2008, 20:26.
15. Wardelmann E, Merkelbach-Bruse S, Pauls K. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res 2006, 15:12.
16. Nishida T, Kanda T, Nishitani A. Secondary mutations in the kinase domain of the KIT gene are predominant in imatinib-resistant gastrointestinal stromal tumor. Cancer Sci 2008, 99:799-804.
17. Pauwels P, Debiec-Rychter M, Stul M, De Wever I, Van Oosterom AT, Sciot R. Changing phenotype of gastrointestinal stromal tumours under imatinib mesylate treatment: a potential diagnostic pitfall. Histopathology 2005, 47:41-7.
18. Liegl B, Kepten I, Le C. Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol 2008, 216:64-74.
19. Liegl B, Hornick JL, Antonescu CR, Corless CL, Fletcher CDM. Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor. Am J Surg Pathol 2009, 33:218-26.
20. Kanda T, Ohashi M, Makino S. A successful case of oral molecularly targeted therapy with imatinib for peritoneal metastasis of a gastrointestinal stromal tumor. Int J Clin Oncol 2003, 8:180-3.
21. Saito M, Sakurai S, Motegi A, Saito K, Sano T, Nakajima T. Comparative study using rabbit-derived polyclonal, mouse-derived monoclonal, and rabbit-derived monoclonal antibodies for KIT immunostaining in GIST and other tumors. Pathol Int 2007, 57:200-4.
22. Cappuzzo F, Hirsch FR, Rossi E. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005, 97:643-55.
23. Walz C, Haferlach C, Hänel A. Identification of a MYO18A-PDGFRB fusion gene in an eosinophilia-associated atypical myeloproliferative neoplasm with a t(5;17)(q33-34;q11.2). Genes Chromosomes Cancer 2009, 48:179-83.
24. Cain JA, Xiang Z, O'Neal J. Myeloproliferative disease induced by TEL-PDGFRB displays dynamic range sensitivity to Stat5 gene dosage. Blood 2007, 109:3906-14.
25. Shimizu A, O'Brien KP, Sjöblom T. The dermatofibrosarcoma protuberans-associated collagen type Ialpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. Cancer Res 1999, 59:3719-23.
26. Bean J, Brennan C, Shih JY. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007, 104:20932-7.
27. Engelman JA, Zejnullahu K, Mitsudomi T. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-43.
28. Zucali PA, Ruiz MG, Giovannetti E. Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors. Ann Oncol 2008, 19:1605-12.
29. Di Renzo MF, Olivero M, Martone T. Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene 2000, 19:1547-55.
30. Seiwert TY, Jagadeeswaran R, Faoro L. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res 2009, 69:3021-31.
31. Rossi G, Valli R, Bertolini F. PDGFR expression in differential diagnosis between KIT-negative gastrointestinal stromal tumours and other primary soft-tissue tumours of the gastrointestinal tract. Histopathology 2005, 46:522-31.